TABLE 1

Percentage of Patients Receiving Ideal Therapy or Beneficial Agent Only, by Type of Therapy and Patient Characteristics

CV BenefitWeight Loss Benefit
Ideal Therapy*Beneficial Agent OnlyIdeal Therapy*Beneficial Agent Only
All patients, unweighted N14697218128
Estimated total nationally, N6,258,6654,109,1488,573,7025,655,308
Estimated total nationally, %3.42.24.73.1
Sex, %
 Male3.62.04.82.9
 Female3.22.54.63.3
Race, %
 White3.32.84.83.8
 Nonwhite3.8NR4.40.5
Age-group, %
 18–54 years5.6§2.97.3§3.5
 55–74 years3.5§2.65.0§3.8
 ≥75 years1.0§0.61.2§1.0
Specialty, %
 Not CV3.52.44.83.3
 CV2.20.63.00.8
Number of unique drugs (all), %
 2–63.22.14.13.0
 7–94.01.46.31.6
 ≥103.52.54.53.2
Comorbidities, %
 Hypertension3.12.24.43.0
 Hyperlipidemia4.02.25.22.9
 Kidney disease0.5*1.21.1#2.8
 Retinopathy4.21.34.72.6
 Kidney disease or retinopathy#1.2#1.21.8#2.5
CCI score, %
 14.7#2.76.3§3.8
 21.5#2.22.0§2.3
 3 or 42.2#1.23.3§2.0
 ≥50.0#1.02.0§2.2
ASCVD status, %
 No4.1§2.45.4§3.2
 Yes1.1§1.82.2§2.7
Obesity status, %**
 No1.8§1.52.7§2.3
 Yes5.1§3.06.8§4.0
  • * Indicates receipt of beneficial agent plus metformin, regardless of other drugs prescribed.

  • Indicates receipt of beneficial agent, but no metformin, regardless of other drugs prescribed.

  • Estimate does not meet one or more criteria for statistical reliability; interpret results cautiously.

  • § P <0.01: Pearson χ2 tests adjusted for complex sampling design; dependent variable was ideal versus nonideal therapy.

  • One drug not shown because, by definition, no patient with only one drug could have ideal therapy.

  • Diagnosis code indicating glomerular filtration rate <60 mL/min/1.73 m2 or chronic condition indicator for CKD or ESRD.

  • # P <0.05: Pearson χ2 tests adjusted for complex sampling design; dependent variable was ideal versus nonideal therapy.

  • ** BMI ≥30 kg/m2 or, for patients with missing BMI, obesity indicator recorded by data collectors.